For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

17th Aug 21

Pharmaxis Grants Aptar Pharma Exclusive Option to Develop and Promote High Payload Dry Powder Inhaler

  • Drug delivery solutions developer Aptar Pharma acquires an exclusive 12-month option for a worldwide license to the “Orbital” technology for $US2.5m plus sales royalties
  • Pharmaxis receives a US$250k upfront fee for the option grant
  • Orbital dry powder respiratory inhaler developed by Pharmaxis delivers large payloads of drug in a convenient easy-to-use format
  • Pharmaxis retains rights to inhaled mannitol products delivered via the Orbital inhaler
Read full media release - pdf
5th Aug 21

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

  • Data Presented from Collaboration of Pharmaxis and University of Rochester Medical Center at US Scientific Meeting
  • Combination of PXS-5505 and Standard of Care Demonstrates a Novel Therapeutic Strategy for Liver Cancer
Read full media release - pdf
4th Aug 21

Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial

  • Second Dose Level in PXS-5505 Myelofibrosis Study Showing Dose Related Increase in Blood Drug Levels and Good Safety Profile in Patients
  • Safety Committee Clear Progression to Final Dose
Read full media release - pdf